NEW YORK (GenomeWeb) — Danaher's Leica Biosystems said today that it has made a deal with Bristol-Myers Squibb to collaborate in developing companion diagnostics to predict which patients will respond to BMS-developed targeted therapies.

Leica said it will create fully automated tissue-based companion diagnostics to run on its Bond automated staining system. These tests will select patients for treatment with pharmaceuticals already developed, or to be developed, by BMS in the future.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.